Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy

INTRODUCTION: Two replicate randomized, placebo-controlled six-month trials (RCTs) and an open-label treatment extension (OLE) comprised the pegloticase development program in patients with gout refractory to conventional therapy. In the RCTs, approximately 40% of patients treated with the approved...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Baraf, Herbert SB, Becker, Michael A, Gutierrez-Urena, Sergio R, Treadwell, Edward L, Vazquez-Mellado, Janitzia, Rehrig, Claudia D, Ottery, Faith D, Sundy, John S, Yood, Robert A
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2013
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3979037/
https://ncbi.nlm.nih.gov/pubmed/24286509
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/ar4318
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados